Abstract
Objective To investigate the prevalence for depressive disorder among HIV-infected population and preliminarily explore the underlying mechanisms.
Methods Individuals who were newly HIV diagnosed were assessed on the Hospital Anxiety and Depression scale (HAD-A and HAD-D). Then SHIV-infected rhesus monkey model was used to investigate the possible involvement of NUCB1 and CB1 protein in depression-like behavior.
Results The prevalence rate of depression disorder among newly confirmed HIV cases was 27.33% (41/150). The mechanism research results showed elevated NUCB1 levels in cerebrospinal fluid (CSF) from HIV-infected patients suffering from depression were confirmed by western blotting compared to those of HIV-infected patients. Also, immunohistochemical analysis indicated expression of NUCB1 in the cerebral cortex neurons of SHIV-infected monkey was higher than that of healthy control. Conversely, CB1 expression were down-regulated at protein level.
Conclusions Depression are common in HIV infection and associate with NUCB1 expression increase, and NUCB1 may be a potential target for depression among HIV-infected subjects.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NO. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been reviewed and approved by the Bioethics and Biological Safety Review Committee of USTC (2021-N(H)-236).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
the data are all contained within the manuscript and/or Supporting Information files, enter the following: All relevant data are within the manuscript and its Supporting Information files.
